Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

The intelligence layer for psychedelic research.

Company

About
Contact
Newsletter

Product

Feedback
Roadmap
Changelog
API
Partners
Clinical Guidelines

Legal

Privacy
Terms

© 2026 Blossom. All rights reserved.

Effects of acute ketamine administration on... — Clinical Trial Details | Blossom

Clinical TrialSchizophreniaKetamineWithdrawn

Effects of acute ketamine administration on mental representations of the body in healthy participants.

This randomised controlled crossover trial (n=20) evaluated the safety and efficacy of ketamine for schizophrenia using 11mg/70kg ketamine.

Ask Blossom about this trial→

Target Enrollment

20 participants

Study Type

interventional

Design

Randomized

Registry

ANZCTR / ACTRN12611000197932

Detailed Description

To determine whether or not acute ketamine administration produces schizophrenic-like changes in the way one's own body is represented mentally.

Study Arms & Interventions

Experimental Arm

experimental

Interventions

Ketamine

Participants

Inclusion Criteria

Healthy participants

Exclusion Criteria

1. Pregnancy or currently breastfeeding
2. Neurological disorders or known seizure risk

Locations

Unknown facility — Australia

3. History of loss of consciousness for over 5 mins

4. Current diagnosis or treatment for a mental illness

5. Past or current treatment for substance use disorder

6. Significant risk of psychoses (previous history of psychosis or first-degree relative diagnosed with schizophrenia/schizophrenia-spectrum disorders)

7. Presence or history of a kinetic disorder

8. Presence or history of hypertension

9. Presence or history of hepatic insufficiency

10. Presence of renal insufficiency

11. Presence or history of cardiovascular disorder

12. Significant risk of suicide

13. Known hypersensitivity to ketamine

14. Receiving any systematic prescription medication (excluding oral contraceptive pill)

Study Details

Status
Withdrawn
Type
interventional
Design
Randomized
Target Enrollment20 participants
Timeline
Start: 2011-08-04
Compound
Ketamine
Topic
Schizophrenia